Objective: To perform a systematic review of prospective studies to confirm the role of breastfeeding in motherto-child transmission (MTCT) of hepatitis B virus (HBV).
breastfeeding group and 873 infants in the nonbreastfeeding group. As indicated by infant peripheral blood hepatitis B surface antigen or HBV DNA positivity at age 6 to 12 months, the odds ratio of MTCT of HBV in the breastfeeding group compared with that in the nonbreastfeeding group was 0.86 (95% confidence interval, 0.51-1.45) (from 8 clinical controlled trials, P = .56; I 2 = 0%, P=.99). As indicated by infant peripheral blood hepatitis B surface antibody positivity at age 6 to 12 months, the odds ratio of development of hepatitis B surface antibodies in the breastfeeding group compared with that in the nonbreastfeeding group was 0.98 (95% confidence interval, 0.69-1.40) ( 1 Approximately 40% to 50% of chronic carrier states are the result of mother-to-child transmission (MTCT), 2 including vertical (intrauterine transmission, transmission during labor, and breastfeeding) and horizontal (daily contact) transmission. Presently, the World Health Organization, the World Gastroenterology Organisation, and the Centers for Disease Control and Prevention recommend joint immunoprophylaxis using hepatitis B vaccine (HBVac) and hepatitis B immunoglobulin (HBIG) at birth to interrupt HBV transmission during and after delivery from HBV-carrying mothers to their newborns. [3] [4] [5] However, these recommendations are aimed at the general HBVcarrying population, most of whom have very low HBV infectiousness (HBV DNA undetectable). Owing to the detection of HBV markers in the breast milk of highly infectious HBV-carrying mothers, there are still controversies concerning the possibility of HBV infection through breastfeeding. 6, 7 This meta-analysis evaluated the role of breastfeeding in HBV MTCT at 6 to 12 months after birth.
METHODS
(CCTs) analyzing the risk of MTCT due to breastfeeding. Queries included articles published from January 1, 1990 , to August 31, 2010 , in English or Chinese peer-reviewed publications (including abstracts). Keywords were "breastfeeding" (or "breast feeding" or "breastfed") and "HBV" (or "hepatitis B virus"). We also hand-searched bibliographies of original studies, reviews (including meta-analyses), and relevant conference abstracts and contacted some investigators directly. The date last searched was September 15, 2010. All newborns (in both breastfeeding and nonbreastfeeding groups) received the schedule of HBIG and/or HBVac immunoprophylaxis beginning within 24 hours after birth as recommended by the World Health Organization.
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STUDY SELECTION
Two of us (Y.Y. and H.W.) independently selected relevant studies, extracted data, and assessed trial quality. Questionable studies were confirmed or rejected by discussion with a third person (L.M.). Inclusion criteria included the following: descriptions of HBV intrauterine infection, MTCT, newborn joint immunoprophylaxis, breastfeeding (Ͼ1 month), and follow-up results (after completion of the immunoprophylaxis schedule) were clear; and mothers in included studies were all hepatitis B surface antigen (HBsAg) seropositive and asymptomatic, had no other infectious diseases or complications (such as human immunodeficiency virus coinfection or severe liver or kidney disease), and were not taking other immunosuppressive medications during pregnancy (Figure 1) . Breastfeeding should have been paused when there were cracked or bleeding nipples or lesions with serous exudates until they recovered. We abstracted data about study design and methods, inclusion and exclusion criteria, clinical characteristics of participants, intrauterine and in-delivery infection, breastfeeding duration and outcomes (MTCT and production of hepatitis B surface antibody [HBsAb] in response to immunoprophylaxis), and adverse events.
For primary outcomes, we estimated the rate of HBV MTCT and production of HBsAb in response to immunoprophylaxis in infants (the observed proportion) at age 6 to 12 months. Secondary outcomes included HBV intrauterine and in-delivery infection, maternal blood and breast milk HBV markers at the beginning of breastfeeding, and adverse events in both mothers (such as transaminase level increase, intolerance to breastfeeding) and their newborns (such as incompatibility to breastfeeding). In the included CCTs, the diagnosis of HBV intrauterine infection and MTCT were defined as neonatal peripheral blood (collected from the femoral artery) HBsAg or HBV DNA positivity at birth and at age 6 to 12 months (collected from the ulnar vein), respectively.
Statistical analyses were conducted using Review Manager version 5.0 software (Cochrane Collaboration, Oxford, England). Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were determined by choice between the MantelHaenszel fixed-effects model and random-effects model, whichever was most conservative (showing less efficacy and a higher P value; the fixed-effects model qualified for this purpose) and shown in forest plot. Statistical between-study heterogeneity was assessed by I 2 test and 2 test. Publication bias was assessed by funnel plot. For all tests, statistical significance was achieved if PϽ.05 (for overall effect of intervention) or PϽ.10 (for heterogeneity test). 8 
RESULTS
Ten qualified studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] were included, all of which were CCTs performed in China. Eight CCTs investigated the role of breastfeeding in MTCT of HBV after joint immunoprophylaxis with HBIG and HBVac in newborns and 3 CCTs examined the same objective after immunization of newborns with only HBVac (Table and Figure 1 ), including 751 infants in the breastfeeding group and 873 infants in the nonbreastfeeding group. According to diagnosis criteria, MTCT of HBV, production of HBsAb, and intrauterine infection (Figures 2, 3 , and 4 according to newborn or infant HBsAg, HBV DNA, or HBsAb seropositivity) as well as maternal blood infectiousness (shown by hepatitis B e antigen [HBeAg] or HBV DNA) ( Figure 5 ) and breast milk infectiousness ( Figure 6 ) were evaluated for comparison purposes. Funnel plots indicating selection bias were also shown in the corresponding comparisons. Figure 1 . Flowchart of study selection and data extraction. Only prospective clinical controlled trials (CCTs) from peer-reviewed journals or conferences were included; CCTs that did not meet the criteria set in the search section were excluded, as were CCTs without enough information about patients' clinical conditions, baseline, treatment of newborns, or follow-up. Authors were further contacted if their names appeared more than once in the included CCTs to rule out duplicate publication of their work. *Cross-included in different database sources or publication in both English and Chinese languages. HBV indicates hepatitis B virus; HBsAb, hepatitis B surface antibody.
PRIMARY OUTCOMES
Breastfeeding vs Nonbreastfeeding in MTCT of HBV at Age 6 to 12 Months
The effect of breastfeeding vs nonbreastfeeding in MTCT of HBV was shown in 2 categories. In infants who received HBIG and HBVac joint immunoprophylaxis, there were 31 positive cases of MTCT of HBV among 637 total participants in the breastfeeding group compared with 33 cases among 706 participants in the nonbreastfeeding group (indicated by infant peripheral blood HBsAg or HBV DNA), with the pooled OR being 0.86 (95% CI, 0.51-1.45) (8 CCTs, P = .56; with mini- Abbreviations: HBeAg, hepatitis B e antigen; HBIG, hepatitis B immunoglobulin; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HBVac, hepatitis B vaccine; IP, immunoprophylaxis; NA, not available; ϩ, positive participants; −, negative participants.
a The HBVac used was of yeast cell origin. b Ratios are number of positive participants/total number of participants in the breastfeeding group:nonbreastfeeding group. When both HBeAg and HBV DNA data (to determine the infectiousness of maternal blood or breast milk) or both HBsAg and HBV DNA data (to determine in utero transmission or mother-to-child transmission) were available, the numbers in bold, which showed a higher percentage of HBV positivity, were used for analysis. The italicized ratios showed a possibility of false positivity or HBV mutants that were resistant to the HBVac.
c Positive for HBsAg and HBeAg in breast milk.
mum heterogeneity, I 2 = 0%, P = .99). In infants who received only HBVac immunoprophylaxis, 6 of 114 participants in the breastfeeding group and 9 of 167 participants in the nonbreastfeeding group had MTCT of HBV, with the OR being 0.95 (95% CI, 0.32-2.81) (3 CCTs, P = .93; I 2 = 0%, P = .85). In infants who received only HBVac immunoprophylaxis and were fed with infectious breast milk (HBsAg or HBV DNA detected in breast milk), the OR was 1.10 (95% CI, 0.30-4.08) (2 CCTs, P =.89; I 2 =0%, P =.68) (Figure 2 
Breastfeeding vs Nonbreastfeeding in Production of HBsAb at Age 6 to 12 Months
The effect of breastfeeding vs nonbreastfeeding in response to immunoprophylaxis was also shown in 2 categories. In infants who received HBIG and HBVac joint immunoprophylaxis, there were 566 cases of HBsAb positivity among 637 participants in the breastfeeding group compared with 625 cases among 706 participants in the nonbreastfeeding group (indicated by infant peripheral blood HBsAb), with the pooled OR being 0.98 (95% CI, 0.69-1.40) (8 CCTs, P = .93; with minimum heterogeneity, I 2 = 0%, P = .99). In infants who received only HBVac immunoprophylaxis, there were 90 cases of HBsAb positivity among 114 participants in the breastfeeding group and 135 cases among 167 participants in the nonbreastfeeding group, with the OR being 0.88 (95% CI, 0.48-1.60) (3 CCTs, P = .68; I 2 = 0%, P = .49). In infants who received only HBVac immunoprophylaxis and were fed with infectious breast milk, the OR was 0.64 (95% CI, 0.28-1.45) (2 CCTs, P=.28; I 2 =0%, P=.75) (Figure 3 ).
SECONDARY OUTCOMES
Incidence of HBV Transmission in Pregnancy and Delivery
To minimize the influence of intrauterine infection or transmission during delivery on the final result of MTCT due to breastfeeding, the newborns' serum-positive rate of HBsAg or HBV DNA at birth was analyzed. In infants who received HBIG and HBVac joint immunoprophylaxis, 61 of 600 newborns had HBsAg or HBV DNA positivity before breastfeeding in the breastfeeding group compared with 69 of 674 newborns in the nonbreastfeeding group, with the pooled OR being 0.99 (95% CI, 0.68-1.44) (7 CCTs, P=.95; with minimum heterogeneity, I 2 =0%, PϾ.99). In infants who received only HBVac immunoprophylaxis, 19 of 114 newborns in the breastfeedinggroupand27of167newbornsinthenonbreast-feeding group had HBsAg or HBV DNA positivity, with the OR being 1.00 (95% CI, 0.52-1.91) (3 CCTs, PϾ.99; I 2 =0%, P=.93) (Figure 4) .
Infectiousness of Maternal Blood and Breast Milk
The influence of infectiousness of maternal blood and breast milk on the final result of MTCT due to breastfeeding was analyzed. Five CCTs studied the infectiousness of maternal blood (shown by HBeAg or HBV DNA positivity) in infants who received HBIG and HBVac joint immunoprophylaxis in the breastfeeding group (141 of 341 infants) vs the nonbreastfeeding group (132 of 332 infants), with the pooled OR being 1.04 (95% CI, 0.74-1.47) (P = .80; with minimum heterogeneity, I 2 = 0%, P =.93). In infants who received only HBVac immunoprophylaxis, 7 of 21 infants in the breastfeeding group and 13 of 41 infants in the nonbreastfeeding group had HBsAg or HBV DNA positivity from maternal blood, with the OR being 1.08 (95% CI, 0.35-3.30) (1 CCT, P=.90) ( Figure 5 with minimum heterogeneity, I 2 = 0%, P = .49). In infants who received only HBVac immunoprophylaxis, 20 of 55 infants in the breastfeeding group and 37 of 79 infants in the nonbreastfeeding group had HBsAg or HBV DNA positivity from breast milk, with the OR being 0.65 (95% CI, 0.32-1.31) (1 CCT, P = .23) (Figure 6 ). There was no report of adverse effects during the process of breastfeeding.
COMMENT
Breast milk is a valuable source of nutrition for infants in general, but in the case of HBV-carrying mothers, the benefit of breastfeeding must be carefully weighed against the risk of transmission of HBV. Based on the results of 2 studies, 19, 20 the World Health Organization recommended breastfeeding by HBV-carrying mothers, reasoning that the "risk of transmission associated with breast milk is negligible compared to the high risk of exposure to maternal blood and body fluids at birth, and hepatitis B vaccination will substantially reduce perinatal transmission and virtually eliminate any risk of transmission through breastfeeding or breast milk feeding." 21 However, it was also stated that "experts on hepatitis did have concerns that breast pathology such as cracked or bleeding nipples or lesions with serous exudates could expose the infant to infectious doses of HBV." 21 Compared with infection during delivery, which is transient and after which the HBV that has entered the neonatal peripheral circulation during the delivery process can be neutralized by the injection of HBIG immediately after delivery, the large amount of breast milk (on average, dozens to hundreds of milliliters per day) in contrast to the immature gastric digestive function and fragile intestine membrane poses continuous risks for HBV transmission. Second, this recommendation was made in 1996, when the test of infectiousness of maternal blood and breast milk by HBV quantitative polymerase chain reaction 22 was not available. It has been reported that colostrum collected within 24 hours from the beginning of breast milk secretion is more infectious (shown by detectable HBV markers). Therefore, breastfeeding needs to be reevaluated to a more detailed extent.
Tang and Xiao 23 performed a meta-analysis that showed a positive correlation between breastfeeding and MTCT of HBV. However, there was no consideration of intrauterine transmission, transmission during delivery, and schedule of immunoprophylaxis after birth. Hence, the result seems to be unconvincing owing to the involvement of MTCT during pregnancy and delivery.
Some studies reported HBV infection as HBsAg and HBV DNA positivity separately, while others summarized them together. Because this study aimed to analyze the risk of breastfeeding in MTCT of HBV, we applied the higher rate when both were available to minimize the influence of intrauterine transmission and transmission during delivery on the outcome of MTCT through breastfeeding.
Hepatitis B immunoglobulin contains high levels of exogenous antibody to HBsAg. This antibody can bind HBsAg, activate the complement system, and facilitate humoral immunity, providing protection for several weeks. Hepatitis B vaccine is made of recombinant HBsAg to induce endogenous HBsAb, which lasts several years. After implementing joint immunoprophylaxis with HBIG and HBVac in the newborn to interrupt HBV MTCT, only 5% to 10% of newborns of HBsAg-and HBeAg-double seropositive mothers were unprotected. 24 Because most HBV infection in infants occurs within the first year of life 25 and the immunoprophylaxis schedules are finished by 6 to 7 months after birth, all studies tested peripheral serum of these infants at age 6 to 12 months to 
